37 related articles for article (PubMed ID: 38652561)
1. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
Kogiso T; Kobayashi M; Yamamoto K; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
Intern Med; 2017 Nov; 56(22):2993-3001. PubMed ID: 28943585
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of urea administration for the treatment of hyponatremia in heart failure.
Martínez González Á; Rodeiro Escobar P; Llópiz Castedo J; Díaz Vázquez M; Sánchez Juanas FL; Villar Carballo M; López Ribera MJ; González Nunes M; Rodríguez Zorrilla S; Rodríguez González A
Med Clin (Barc); 2024 Jan; 162(2):56-59. PubMed ID: 37798246
[TBL] [Abstract][Full Text] [Related]
3. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
4. Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan.
Hanna RM; Velez JC; Rastogi A; Nguyen MK; Kamgar MK; Moe K; Arman F; Hasnain H; Nobakht N; Selamet U; Kurtz I
Kidney Med; 2020; 2(1):20-28. PubMed ID: 32734225
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.
Kim Y; Lee N; Lee KE; Gwak HS
Eur J Clin Pharmacol; 2020 May; 76(5):723-729. PubMed ID: 32055900
[TBL] [Abstract][Full Text] [Related]
7. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
8. Comparative Safety and Effectiveness of Urea and Tolvaptan for the Management of Hyponatremia.
Scalla PA; Palma SM; Dittmar E; Zamora FJ; Trimino E
J Pharm Pract; 2024 Apr; ():8971900241247617. PubMed ID: 38652561
[No Abstract] [Full Text] [Related]
9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
10. Hyponatremia, heart failure, and the role of tolvaptan.
O'Connell JB; Alemayehu A
Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Hyponatremia: A Review.
Adrogué HJ; Tucker BM; Madias NE
JAMA; 2022 Jul; 328(3):280-291. PubMed ID: 35852524
[TBL] [Abstract][Full Text] [Related]
12. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
Friedman B; Cirulli J
J Crit Care; 2013 Apr; 28(2):219.e1-12. PubMed ID: 22884529
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
